Addressing the oxamniquine in vitro-in vivo paradox to facilitate a new generation of anti-schistosome treatments

Addressing the oxamniquine in vitro-in vivo paradox to facilitate a new generation of anti-schistosome treatments

The antischistosomal drug oxamniquine, OXA, requires activation by a sulfotransferase within the parasitic worm to enable killing. Examination of the pharmacokinetic/pharmacodynamic (PK/PD) relationship for OXA identified an in vitro-in vivo paradox with the maximal clinical plasma concentrations fi...

Full description

Bibliographic Details
Main Authors: Katalin Toth, Sevan Alwan, Susan Khan, Stanton F. McHardy, Philip T. LoVerde, Michael D. Cameron
Format: Article
Language:English
Published: Elsevier 2023-04-01
Series:International Journal for Parasitology: Drugs and Drug Resistance
Subjects:
Oxamniquine
Schistosome
Schistosomiasis
Parasitic worm
PK/PD relationship
Online Access:http://www.sciencedirect.com/science/article/pii/S2211320723000039

Similar Items

Similar Items